Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

7.480 +0.180 (+2.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 766,149
Open 7.270
Bid (Size) 7.260 (200)
Ask (Size) 7.480 (100)
Prev. Close 7.300
Today's Range 7.169 - 7.550
52wk Range 4.010 - 54.97
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗
They could both outperform the market over the medium term, but one appears to have a clear edge. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
-80.9%
-80.9%
1 Month
+66.2%
+66.2%
3 Month
-77.8%
-77.8%
6 Month
-80.4%
-80.4%
1 Year
-65.4%
-65.4%

More News

Read More
News headline image
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
From Pomerantz LLP
Via GlobeNewswire
News headline image
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead ↗
Via The Motley Fool
News headline image
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Sionna Therapeutics, Inc. (SION) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information
From Robbins LLP
Via Business Wire
News headline image
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗
Via The Motley Fool
News headline image
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION)
From Levi & Korsinsky, LLP
Via Business Wire
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Via Benzinga
News headline image
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path ↗
Via MarketBeat
News headline image
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗
Via The Motley Fool
News headline image
Sionna Therapeutics Reports Second Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports First Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 7.480
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 09/09/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.